Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. Catheter ablation has become an important treatment option for many AF patients. Catheter ablation has been hypothesized to reduce the need for continued medical therapy for patients with AF, but there are few empirical data which demonstrate this.
Background
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. The prevalence of AF, which increases with age, is estimated at 0.4% of the general population. 1 In addition to reducing health-related quality of life 2 and exposing patients to increased risks of heart failure and stroke, 3, 4 AF is also an expensive condition to treat, with recent studies projecting AF treatments costs in the United States as high as $10-$20 billion annually. 5, 6 Catheter ablation has become an important treatment option for many AF patients. Demonstrated benefits of AF ablation, relative to antiarrhythmic drug (AAD) therapy include superior maintenance of sinus rhythm, 7, 8 improved quality of life 9 and possibly reduced hospitalization. 10 Several published health economic analyses comparing ablation to AAD therapy have postulated that ablation, by reducing arrhythmia recurrence, may decrease long-term resource utilization and overall AF treatment costs. [11] [12] [13] Empirical evidence supporting this hypothesis is limited, particularly from general clinical practice. One previous study documented a reduction in drug expenditures following catheter ablation, but did not include a reference group not receiving ablation. 14 The aim of this study was to compare AAD drug utilization and costs longitudinally in AF patients treated with catheter ablation versus those treated with AAD drugs but no ablation. This was done using a large, national claims database. The hypothesis was that patients treated with ablation would have reduced drug utilization and costs over time relative to those treated without ablation. In order to assess the potential impact of catheter ablation and drug expenditures specifically in Medicare-eligible patients, the analysis was stratified at an age cutoff of 65 years.
Methods

Data Source and Study Population
This study analyzed data from the U.S. MarketScan ® Commercial Claims and Encounters Database and Medicare Supplemental Database from Truven Health Analytics SM (New York, NY). 15 The databases are comprised of de-identified patient-level records from over 121 million patients since 1995 enrolled in employer-sponsored and public health insurance plans. In particular, they include data from 150 employers spanning several states. The MarketScan ® Databases have been previously used for a variety of health services research studies and are in compliance with the Health Information Portability and Accountability Act of 1996. A protocol describing the study objectives, criteria for patient selection, data elements of interest, and statistical methods was submitted to the New England Institutional Review Board (NEIRB) and deemed exempt from review.
Patient-level data were extracted from the MarketScan Databases, covering the period between the first quarter of 2005 and the first quarter of 2009. Patients eligible for inclusion in the analysis were ≥18 years of age and had a primary diagnosis of AF (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9] diagnosis code 427.31). 16 In addition, all patients were required to have 6 months of continuous medical and pharmacy enrollment in the database immediately prior to their respective baseline time and 1 year of continuous enrollment follow-up immediately afterwards.
Patients with AF were divided into ablation and AAD only groups using coding algorithms, as previously described. 17 Those in the ablation cohort were required to have an inpatient or outpatient visit with both a recorded diagnosis of AF and a documented catheter ablation procedure (ICD-9 code 37.34 or Current Procedural Terminology [CPT] code 93651). Patients with coexisting diagnoses for other supraventricular tachycardias or a procedure code for atrioventricular (AV) junction ablation, pacemaker or implantable cardioverter defibrillator insertion were excluded. For inpatient encounters, the ICD-9 codes for AF and catheter ablation were required to be designated as the primary diagnosis and procedure associated with the visit. A record of any cardiac ablation procedure in the six months prior to the procedure meeting the above requirements caused a patient to be excluded from the analysis. The analytic start time was defined for this cohort as the date of the first catheter ablation procedure meeting the inclusion/exclusion criteria.
Patients in the non-ablation cohort were also required to have a diagnosis of AF, but could not have any record of an ablation procedure. Additionally, they had to have documentation of at least two AAD prescription fills after their first recorded AF diagnosis. The first record of the second antiarrhythmic medication was then used as the analytic start time for this cohort.
Baseline patient characteristics were defined from available claims data in the 6 months prior to the analytic start time, including demographics, the presence or absence of comorbid conditions, history of medication usage for drug categories of interest, history of electrical cardioversion, and utilization of medical services. Demographics and other general descriptive variables included age, sex, procedure setting (inpatient/ outpatient), year of procedure, insurance and patient location variables, length of primary ablation hospital stay, and length of time in the database. The comorbid conditions of interest included various categories of structural heart disease, hypertension, diabetes, chronic obstructive pulmonary disease (COPD) and acute renal failure (Table 1) .
Outcomes
Two outcomes of primary interest were defined: the likelihood of AAD usage, and overall prescription drug costs -including both insurer payments and patient co-payments -during pre-specified follow-up intervals. The reference period for this analysis was the 6 months prior to the first ablation procedure, or second AAD prescription (in patients not treated with ablation). AAD treatment was defined as a prescription fill for a Vaughan-Williams Class I or Class III antiarrhythmic drug 18 (i.e. propafenone, flecainide, sotalol, dofetilide, or amiodarone) at any time during a given 6-month interval. In order to compare follow-up results to the baseline period, these two outcomes were assessed in subsequent 6-month intervals, beginning with 6-12 months after the analytic start time. The interval from 0-6 months was not included, as this is often a period of medication titration or, in the case of ablation, repeat procedures and the intent of the study was to examine longer-term outcomes. This is analogous to a 6-month "blanking period", 3-month blanking is utilized in AF ablation clinical trials. 19, 20 Follow-up was truncated at 3 years, as few patients had continuous claims data available for longer than this.
Statistical Analysis
The primary objective was to compare longitudinal drug utilization and costs between AF patients who were and were not treated with ablation. Given that patient selection for catheter ablation in our study was non-random, significant baseline differences between the ablation and non-ablation patient groups were expected. Propensity matching was used to address these potential imbalances in baseline patient characteristics. Propensity scores for receipt of a catheter ablation were calculated for each of the patients included in the analysis based on a multivariable logistic regression model. This stepwise approach used 15 patient characteristics hypothesized to be associated with having a catheter ablation. These included: age group, gender, region of country, total enrollment in months, number of office visits, number of emergency department visits, rhythm medication usage (at baseline), warfarin usage, stroke or transient ischemic attack (TIA), COPD, heart failure, coronary artery disease, hypertension, cardiomyopathy and diabetes. Based on the propensity for having a cardiac catheter ablation procedure, ablation and non-ablation patients identified using our coding algorithm were matched with a four-digit nearest neighbor algorithm. The matching criteria were intentionally strict, knowing that a number of the ablation patients would not be found to have suitable non-ablation matches, in order to make the matched ablation and non-ablation cohorts as similar as possible. Note: Clinical and demographic characteristics are described in the baseline period, 6 months pre-index. The first record of the second antiarrhythmic medication is defined by attrition rules as index or day 0 for the non-ablation group; CDHP: consumer driven health plan; COPD: chronic obstructive pulmonary disease; EPO: exclusive provider organization; HDHP: high deductible health plan; HMO: health maintenance organization; POS: point of service; PPO: preferred provider organization; MI: myocardial infarction; SD: standard deviation
Results
Population Characteristics
Using the coding algorithm described above, 2,645 patients were identified as meeting study entry criteria who underwent a first catheter ablation procedure for AF between 2005 and 2009 (Supplemental Figure 1 ). Of these patients, 761 were ≥ age 65. In addition, 7,162 AF patients were identified as treated with at least two AADs but not ablation (Supplemental Figure 2 ). Of these, 4,672 were age ≥65.
Baseline clinical and demographic characteristics of the ablation and non-ablation patients are summarized in Table 1 . In the entire population, the majority of patients were male and insured by a preferred provider organization (PPO). Patients undergoing AF ablation compared with patients who did not receive the procedure were younger (mean 59.2 vs. 69.0 years) and were more often male (72% vs. 55%), and insured by a PPO (53% vs. 43%). The differences in age and gender persisted in the age ≥65 sample. Moreover, patients undergoing catheter ablation for AF were less likely to have certain comorbidities, such as heart failure, hypertension, COPD and diabetes. The lower panel of Table 1 reports summary statistics for the two outcome variables in the 6 months prior to the ablation procedure or second AAD prescription. As expected, the proportion of patients receiving AADs in the 6-month baseline period was higher in the ablation versus non-ablation groups. Despite this, total baseline drug expenditures were similar (<$200 difference) for both groups. After matching, age, gender, comorbidities and medication utilization were balanced between the ablation and medication cohort ( Table 1) .
Antiarrhythmic Drug Utilization
The frequency of AAD utilization over time for the ablation and non-ablation groups within the propensitymatched sample (N=1,602) is shown in Figure 1A . In the 6 months prior to the analytic start time, just under 80% of patients in both groups had been treated with AADs. In the non-ablation group, AAD use fell gradually to just over 60% between 2.5 and 3 years. AAD use fell more quickly and remained near 40% after 12 months in the ablation group. Results were similar in the older subset of patients ( Figure 1B) , although AAD use in older patients not treated with ablation fell to a slightly greater extent.
Results of the regression models on the outcome of AAD use per 6-month interval are shown in Table  2 . Results were similar across levels of multivariable adjustment. As indicated by the ablation by time interaction terms (top row of results in table), in the matched sample patients treated with ablation were 25-37% less likely to be treated with AADs during follow-up than patients not treated with ablation. Results were similar in the matched sample of patients age 65 and over, as shown in the lower panel of Table 2 . Results are displayed for five samples, based on duration of available follow-up time post ablation. For each post-ablation period, two sets of results are reported. § The first includes no controls (first column) and the second presents the most saturated model, which includes all clinical and demographic controls (second column). For patients matched on clinical dimensions at the baseline, the effect of ablation was stronger, with the likelihood of using rhythm medications falling approximately 30%.
Overall Prescription Drug Expenditures
Results of the regression models on the outcome of total prescription drug expenditures are shown in Table  3 . The difference between the ablation group and non-ablation group in semi-annual drug costs is shown graphically in Figure 2A and in Figure 2B for the subset of patients aged ≥65 years. These differences were roughly $400-$600 (per 6 months) for the full matched sample, and $200-$400 for patients age ≥65. 
Discussion
This study found that catheter ablation in patients with AF was associated with a clinically significant and durable reduction in rhythm medication utilization, as compared with AAD treatment without ablation. These reductions were concomitant with declines in overall medication expenditures. The results were similar in a sub-analysis of patients who were age ≥65, although savings on total prescription drug expenditures in this population were slightly smaller.
These findings to some extent validate assumptions made in several previous health economic analyses of AF ablation regarding long-term medical therapy costs, [11] [12] [13] and have the advantage of being based on data from patients in general U.S. practice. The results are, therefore, likely to be generalizable to the patients currently being managed with AF ablation across the country.
From a clinical perspective, the continued use of AADs in patients undergoing AF ablation may be slightly higher than expected, but most likely not by a large margin. Both a previous meta-analysis of AF ablation studies and a voluntary worldwide survey on AF ablation found that the rate of repeat procedures after a first AF ablation is in the range of 25%, 21, 22 and randomized trials of AF ablation for paroxysmal AF have reported 12 month rates of freedom from atrial arrhythmia of 65-70%. 20, 23 Since the adjunctive use of AADs may improve the results of ablation, 21 the observation that roughly 40% of patients continued AAD therapy may be a realistic representation of results in general clinical practice, though one not previously reported with up to 3 years of follow-up. These results are also consistent with prior literature reagarding AF patients not treated with catheter ablation, documenting relatively high rates of AAD discontinuation due to both adverse events and inefficacy. [24] [25] [26] Few previous studies have documented the potential cost savings that may be associated with reductions in prescription drug utilization following AF ablation. Using a similar data source, Ladapo et al. 14 recently showed reductions in multiple categories of healthcare resource utilization, including prescription drug costs, after AF ablation, compared with prior to ablation, but that study did not include a comparison group of AF patients treated with AADs and not ablation. Shah and colleagues 27 also recently reported on outcomes after AF ablation using a California claims database, documenting a 30% rate of readmission for atrial arrhythmia or repeat ablation over 2 years, but their study did not examine prescription drug use or costs.
Limitations
These data should be interpreted with the following limitations in mind. First and most importantly, the clinical decision to perform catheter ablation on an AF patient is not a random one, as evidenced by the marked differences between the ablation and non-ablation patients in this study prior to propensity matching. It is clear that patients selected for ablation are younger and healthier than those not treated with ablation.
Multiple techniques were used to adjust for these expected and observed differences between patient groups, including propensity matching and multivariable regression modeling. Only a large-scale randomized trial would be able to control for potential unmeasured confounders, however recent randomized trials in this field have been characterized by high rates of crossover from drugs to ablation, which would preclude the kinds of comparisons done in this study.
This study is also subject to the usual limitations of research done using claims data. The Medicare sample used in this analysis consists of patients that have Medicare supplemental insurance (e.g. Medicare Advantage plans), which, on average, include patients with slightly higher socioeconomic status compared to Medicare Fee-for-Service patients. Additionnally, during the period of the study, there was not a unique billing code for AF ablation, thus the case finding relied on a coding algorithm which was designed with high specificity by excluding patients who might have had procedures for arrhythmias other than AF.
In addition to potential inaccuracies inherent in claims data, this type of data source also lacks clinical detail. It was not possible to tell, for example, what the success rates of either AAD treatment or catheter ablation were in suppressing AF, or what the reasons were for discontinuing AADs in any particular patient. Since AAD use fell sharply (within 12 months) in the ablation group and more gradually (over 2-3 years) in the non-ablation group, it is tempting to suggest that the reasons for drug discontinuation may have differed between groups. Linkage with a richer clinical data source would be required to understand this.
Conclusion
AF patients treated with catheter ablation are significantly more likely to discontinue AADs over a 2-to 3-year period than patients initially treated with AADs, but not ablation. This was associated with savings of as much as $800-$1,200 per year in overall prescription drug expenditures in some patient groups, but more modest reductions in older patients. These data support the view that the up-front costs of AF ablation are at least partially offset by decreased health resource utilization over time.
